Cardiovascular involvement in systemic sclerosis;Atteinte du cœur et des vaisseaux au cours des sclérodermies systémiques

Annales de Medecine Interne

Volumn 153, Issue 4, 2002, Pages 242-249

  Constans, Joël ^a   Skopinski, Sophie ^a   Barcat, Damien ^a   Conri, Claude ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Arteriopathy; Cardiomyopathy; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

PROSTACYCLIN;

ARTERY DIAMETER; ARTERY DISEASE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CORONARY ARTERY; DIAGNOSTIC IMAGING; DIASTOLE; DOPPLER ECHOGRAPHY; DRUG INFUSION; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HUMAN; IMAGE ANALYSIS; MICROCIRCULATION; PATHOGENESIS; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SCINTISCANNING; SYNDROME CREST; SYSTEMIC SCLEROSIS; VASOSPASM; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY;

CARDIOMYOPATHIES; CREST SYNDROME; DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS; SCLERODERMA, SYSTEMIC;

EID: 2242465532     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Pathologic observations in systemic sclerosis (Scleroderma): A study of fifty-eight autopsy cases and fifty-eight matched controls
2. Pericardial disease in scleroderma (systemic sclerosis)
3. Myocardial lesions of progressive systemic sclerosis: A cause of cardiac dysfunction
4. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): A high risk association
5. Echocardiographic identifications of cardiac abnormality in scleroderma and related disorders
6. Abnormal ventricular long-axis function in systemic sclerosis
7. Non-invasive assessment of systolic left ventricular function in systemic sclerosis
8. Non-invasive assessment of left ventricular diastolic function in patients with systemic sclerosis
9. Cardiac involvement in systemic sclerosis
10. Left ventricular wall motion abnormalities in 80 patients with systemic sclerosis
11. Diastolic abnormalities in systemic sclerosis: Evidence for associated defective cardiac functional reserve
12. Heart involvement in systemic sclerosis: An ultrasonic tissue characterization study
13. Autonomic dysfunction in systemic sclerosis: Time and frequency domain 24 hour heart rate variability analysis
14. The electrocardiogram in scleroderma: Analysis of 60 cases and review of the literature
15. The prevalence of conduction defects and cardiac arrythmias in progressive systemic sclerosis
16. The electrocardiogram in systemic sclerosis (scleroderma): Study of 102 consecutive cases with functional correlations and review of the literature
17. Heart disease in systemic sclerosis
18. QT interval and QT dispersion in systemic sclerosis (scleroderma)
19. Atrioventricular nodal function in progressive systemic sclerosis: Electrophysiological and morphological findings
20. The cardiac conduction system in progressive systemic sclerosis. Clinical and pathologic features of 35 patients
21. Atrial involvement in patients with progressive systemic sclerosis: Relationship between ultrasonic tissue characterization of the atrium and interatrial conduction
22. Non invasive assessment of myocardial involvement in patients with systemic sclerosis: Role of signal averaged electrocardiography
23. Failure of the circulatory system limits exercise performance in patients with systemic sclerosis
24. Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis
25. Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis
26. Myocardial gallium-67 citrate scintigraphy in patients with systemic sclerosis
27. Thallium-201 myocardial SPET in patients with collagen disease
28. Diastolic dysfunction in patients with systemic sclerosis detected by gated myocardial perfusion SPECT: An early sign of cardiac involvement
29. 99mTc SESTA-MIBI scintigarphic evaluation of skeletal muscle disease in patients with systemic sclerosis: Diagnostic reliability and comparison with cardiac funtion and perfusion
30. Early diagnosis of cardiac involvement in systemic sclerosis by 123I-MIBG neurotransmitter scintigraphy
31. Scleroderma heart disease with slow flow velocity in coronary arteries
32. Decreased coronary reserve in primary scleroderma myocardial disease
33. Reduced coronary flow and resistance reserve in primary scleroderma myocardial disease
34. Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis
35. Left ventricular dysfunction induced by cold exposure in patients with systemic sclerosis
36. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis
37. Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma
38. Left ventricular myocardial perfusion in systemic sclerosis before and after diltiazem treatment
39. Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomized study (ESS-1): ECG exercise testing-three months follow-up
40. Enalapril (10 mg/day) in systemic sclerosis. One year, double blind, randomized study (ESS-1): Echocardiographic substudy-three months follow-up
41. The heart in scleroderma
42. Pathologic observations in systemic sclerosis (scleroderma): A study of fifty-eight autopsy cases and fifty-eight matched controls
43. Echocardiogaphic features of progressive systemic sclerosis (PSS)
44. Heart involvement in systemic sclerosis: A prospective case-control study in 59 patients
45. Pericardial involvement in systemic sclerosis
46. Frequency of mitral valve prolapse in systemic lupus erythematosus, progressive systemic sclerosis and mixed connective tissue disease
47. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients
48. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma)
49. Comparison of doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis
50. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients
51. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension
52. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis
53. Systemic sclerosis-associated pulmonary hypertension: Short- and long-term effects of epoprostenol (prostacyclin)
54. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
55. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis
56. The pathological changes in the arteries supplying the fingers in warm-handed people and in cases of so-called Raynaud's disease
57. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon
58. Digital ateries in patients with systemic scleroderma
59. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis
60. Limited scleroderma is associated with increased prevalence of macrovascular disease
61. Distribution of macrovascular disease in scleroderma
62. Macrovascular disease and systemic sclerosis
63. Alteration of arterial distensibility in systemic sclerosis
64. The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study
65. Nicardipine improves myocardial perfusion in systemic sclerosis
66. Pharmacodynamic effect of nicardipine on left ventricular function in systemic sclerosis
67. Effect of diltiazem on cold-induced left ventricular dysfunction in patients with systemic sclerosis
68. Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors
69. The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis
70. Short- and long-term hemodynamic effects of captopril in patients with pulmonay hypertension and selected connective tissue disease
71. Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril